Phaseline

Targets › ERCC1

ERCC1 (DNA excision repair protein ERCC-1): drug programs, companies and trials

6 programs from 6 companies in 16 trials: 9 Phase 4, 5 Phase 2, 2 Phase 3; Oncology, Cardiovascular, Immunology; next expected readout Dec 2026.

[Isoform 1]: Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). (UniProt, P07992)

Open in Phaseline: the race on ERCC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bausch Health AmericasClindamycin
Bacterial 70S ribosome inhibitor
ERCC1, ERCC2Phase 4Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection …Dec 2027
Sun Yat-sen UniversitymFOLFOXIRI
Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan
TOPO1, TOPO2A, ERCC1Phase 3Colon Cancer Stage IIDec 2026
Ruijin HospitalOxaliplatin plus S-1
Platinum-based DNA crosslinking agent combined with fluoropyrimidine antimetabolite
ERCC1Phase 3Gastric Cancer (GC); Gastric or Esophagogastric Junction AdenocarcinomaApr 2028
Peking Union Medical College HospitalGC
Combination of gemcitabine and cisplatin
RRM1, RRM2, DCK, ERCC1Phase 2Biliary Tract Neoplasms ImmunotherapyJan 2027
Shandong Cancer Hospital and InstituteNALIRIFOX
Combination chemotherapy with liposomal irinotecan (topoisomerase I inhibitor), oxaliplati
TOP1, ERCC1Phase 2Pancreatic CancerOct 2028
Institut du Cancer de Montpellier - Val d'Aurellemodified FOLFIRINOX regimen
Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr
TOPO1, TOPO2A, ERCC1Phase 2Locally Advanced Malignant NeoplasmSep 2029

Conditions

Acne Vulgaris (2) Skin Infection (1) Infection Control / Methods (1) Surgical Site Infection (1) Endocarditis Infective (1) Wisdom Tooth Removal (1) Cat Bite (1) Staphylococcus Aureus Bacteremia (1) Aortic Surgery (1) Pancreatic Cancer (1) Colon Cancer Stage II (1) Biliary Tract Neoplasms Immunotherapy (1)

Modalities

small molecule (4)

Companies

Bausch Health Americas (1) Shandong Cancer Hospital and Institute (1) Sun Yat-sen University (1) Peking Union Medical College Hospital (1) Ruijin Hospital (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)

Related targets

TOPO1 (2) TOPO2A (2) ERCC2 (1) TOP1 (1) RRM1 (1) RRM2 (1) DCK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.